News release service Business Wire has reported a fake press release involving Javelin Pharmaceuticals Inc. (JAV) that ran on its service Friday night to the Federal Bureau of Investigation, Business Wire Chief Executive Cathy Tamraz said.

The FBI couldn't immediately be reached. Tamraz said her firm has reported the case to the New York bureau of the FBI, and the case is being treated as a "criminal investigation."

Javelin Pharmaceuticals Monday morning announced that on June 18 Business Wire inadvertently issued a hoax press release titled "US Supreme Court split -- rules in favor of Big Pharma" that falsely identified Javelin Pharmaceuticals as the issuer of the information. The information in the hoax release was false, Javelin's statement said. Business Wire received the hoax release from an unknown third party, purporting to be an authorized representative of the company, Javelin's Monday statement said.

-By Anjali Cordeiro, Dow Jones Newswires; 212-416-2200; anjali.cordeiro@dowjones.com

 
 
Javelin Pharmaceuticals (AMEX:JAV)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Javelin Pharmaceuticals.
Javelin Pharmaceuticals (AMEX:JAV)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Javelin Pharmaceuticals.